ArticlePloS one2026
Overexpression of miR-149 attenuates opioid-related perturbations in neural stem cell fates and serves as a translational biomarker for infants with prenatal opioid exposure.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
There is currently no biomarker to predict the maximum morphine dose (MMD) for newborns experiencing withdrawal from chronic prenatal opioid exposure (POE). This is due, in part, to a lack of understanding about how the developing brain is altered by chronic opioid exposure and withdrawal on a molecular level. We previously developed a human induced pluripotent stem cell-derived model of POE and withdrawal to examine the impact on neural progenitor cell fates. Here, we leveraged our model to investigate the role of two microRNAs implicated in both neural stem cell differentiation and opioid signaling: miR-149 and miR-23b. Further, we asked if these microRNAs were related to the need for morphine treatment and MMD in the saliva of infants with POE. Levels of miR-149 (One-way ANOVA, F = 34.18, p < 0.0001), but not miR-23b (One-way ANOVA, p = 0.14), were significantly decreased in human neural progenitors after chronic morphine exposure (Tukey's, adj. p = 0.004), and decreased further in those that underwent withdrawal compared to vehicle exposed controls (Tukey's, adj. p < 0.0001). The relevance of miR-149 to neonates experiencing withdrawal after POE was confirmed by decreased salivary levels of miR-149 compared to levels in healthy infants 24-96 hours after birth (n = 56, 28 unexposed and 28 infants with POE) (Mann-Whitney U, p < 0.0001). Stratifying infants with POE by need for pharmacotherapy revealed a further decrease in levels of miR-149 in infants that required treatment (One-way ANOVA, p < 0.0001). In a hierarchical linear regression model utilizing infant demographic factors, addition of miR-149 levels in neonatal saliva improved performance for predicting the MMD necessary for symptom control (R = 0.673, p = 0.002). These results indicate the potential relevance of miR-149 levels in infants with prenatal opioid exposure. Validation in larger cohorts is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.